ReviewThe Journal of clinical investigation2005
Host-based antipoxvirus therapeutic strategies: turning the tables.
Review in The Journal of clinical investigation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Role of MAPK/MNK1 signaling in virus replication.Virus research · 2018Review
- Comparative Characterization of the Sindbis Virus Proteome from Mammalian and Invertebrate Hosts Identifies nsP2 as a Component of the Virion and Sorting Nexin 5 as a Significant Host Factor for Alphavirus Replication.Journal of virology · 2018Article
- Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Variola virus F1L is a Bcl-2-like protein that unlike its vaccinia virus counterpart inhibits apoptosis independent of Bim.Cell death & disease · 2015Article
- The DNA helicase-primase complex as a target for herpes viral infection.Expert opinion on therapeutic targets · 2013Review
- Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
- Smallpox inhibitor of complement enzymes (SPICE): regulation of complement activation on cells and mechanism of its cellular attachment.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS).Biologics : targets & therapy · 2007Article
- Synthesis and antiviral activities of new acyclic and "double-headed" nucleoside analogues.Bioorganic chemistry · 2007Article
- Toward orthopoxvirus countermeasures: a novel heteromorphic nucleoside of unusual structure.Journal of medicinal chemistry · 2006Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential threat of the smallpox virus as a bioterror weapon has long been recognized, and the need for developing suitable countermeasures has become especially acute following the events of September 2001. Traditional antiviral agents interfere with viral proteins or functions. In a new study, Yang et al. focus instead on host cellular pathways used by the virus. A drug that interferes with the cellular ErbB-1 signal transduction pathway, activated by smallpox growth factor, sheds new light on how the virus replicates in the cell. Drugs that target the ErbB-signaling pathways represent a promising new class of antiviral agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.